Newsletter | December 11, 2024

12.11.24 -- The FDA's Psychedelic Reckoning

SPONSOR

Break Down Roadblocks To Commercial Manufacturing Success

Selection and implementation of a commercial manufacturing strategy is among the most critical decisions a biopharmaceutical company will make. Rely on an experienced CDMO partner with the ability to maximize the quality and cost-effectiveness of your antibody process at commercial scale. Explore key considerations for process optimization and process validation here.

FROM THE EDITOR

FDA's Psychedelic Reckoning

Cybin CEO Doug Drysdale discusses learnings from psychedelic drug clinical trial missteps, provides examples of the benefits of FDA breakthrough therapy designation, and talks about why RFK Jr. as HHS Secretary could be a win for psychedelic drug developers.

INDUSTRY INSIGHTS

Breaking The Mold: How R Is Revolutionizing CSR Generation

The open-source statistical programming language R is becoming more popular in the life sciences sector for clinical study report submissions due to its cost-effectiveness, inclusivity, and collaboration.

Broadening Bioconjugate Design, Development To Develop Better Medicines

ADCs have the potential to reshape cancer treatment, but realizing their full therapeutic promise requires addressing critical challenges in drug design, delivery, and safety.

Middlesex County, NJ: A Diverse Talent Pool and Rich Resource Base

Middlesex County, NJ, offers life sciences organizations a deep talent pool, an extensive R&D presence, and dedicated backing by local government investment.

Mitigating Early Development Risks

Discover how the efficient screening of biologic candidates accelerates the discovery process, reduces costs, and improves the likelihood of commercializing safe and effective drugs.

Empowering A New Era Of Patient-Centric Medicines

Review the challenges pharma companies are facing as they switch focus as well as the actions and technologies companies are implementing to help achieve a brighter future for patients.

Overcoming Common Challenges Of Clinical Data Review

Look at some of the main challenges of clinical data review and effective strategies to address these, as well as solutions that can be deployed to bring urgently needed therapeutics to patients faster.

Patient Experience: Benefits, Strategies, And FAQs

Patient experience encompasses all patient interactions with healthcare providers. Improving communication, setting expectations, and fostering trust enhances safety and overall care satisfaction.